We knew that when Sean Salmon took over the diabetes franchise that he’d be swimming upstream against the tide. The unit besieged by multiple issue was in serious need of overhaul and it was Mr. Salmon job to turn things around. Tandem and Insulet were forging ahead developing newer, better systems and were beginning to eat away at the company’s huge installed user base. Their CGM was a complete disaster and had frankly became an embarrassment making then CEO Omar Ishrak look like a fool for stating the stand-alone system would become a multi-billion-dollar franchise . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.